Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC

J Thorac Oncol. 2021 Apr;16(4):532-536. doi: 10.1016/j.jtho.2020.12.021.

Authors

Misako Nagasaka¹, Sai-Hong Ignatius Ou²

Affiliations

¹ Karmanos Cancer Institute, School of Medicine, Wayne State University, Detroit, Michigan; Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
² Division of Hematology/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. Electronic address: siou@hs.uci.edu.

PMID: 33781444
DOI: 10.1016/j.jtho.2020.12.021

No abstract available

Publication types

Editorial

MeSH terms

Aminopyridines
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Humans
Lactams
Lactams, Macrocyclic
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Protein Kinase Inhibitors / therapeutic use
Pyrazoles
Receptor Protein-Tyrosine Kinases / genetics

Substances

Aminopyridines
Lactams
Lactams, Macrocyclic
Protein Kinase Inhibitors
Pyrazoles
Receptor Protein-Tyrosine Kinases
lorlatinib